Cambridge-based clinical-stage biotechnology company STORM Therapeutics, focused on developing cancer treatments by targeting RNA modifications, has announced a significant $56 million Series C funding round. This latest investment was entirely supported by its existing investors, including prominent venture capital arms Pfizer Ventures and M Ventures.
The capital infusion will be instrumental in furthering the development of STC-15, a groundbreaking therapeutic candidate. STC-15 holds the distinction of being the world’s first inhibitor of RNA-modifying enzymes to advance into human clinical trials. Early results from Phase 1 trials have demonstrated promising outcomes, showing sustained tumor regression across a variety of sarcoma subtypes.
This successful funding round underscores the confidence of STORM Therapeutics’ investors in the company’s innovative approach to cancer therapy and the potential of STC-15 to address unmet medical needs.
English Translation:
Cambridge-based clinical-stage biotechnology company STORM Therapeutics, focused on developing cancer treatments by targeting RNA modifications, has announced a significant $56 million Series C funding round. This latest investment was entirely supported by its existing investors, including prominent venture capital arms Pfizer Ventures and M Ventures.
The capital infusion will be instrumental in furthering the development of STC-15, a groundbreaking therapeutic candidate. STC-15 holds the distinction of being the world’s first inhibitor of RNA-modifying enzymes to advance into human clinical trials. Early results from Phase 1 trials have demonstrated promising outcomes, showing sustained tumor regression across a variety of sarcoma subtypes.
This successful funding round underscores the confidence of STORM Therapeutics’ investors in the company’s innovative approach to cancer therapy and the potential of STC-15 to address unmet medical needs.
